ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Comparative analysis of human telomerase reverse transcriptase mutation in transitional epithelial cell bladder cancer in high and low grade tumors
Abstract
Aims: We aimed to evaluate the presence of TERT promoter region mutations in transitional epithelial cell bladder cancer by analyzing the h-TERT mutation in high and low-grade tumors and to compare it with the clinicopathological data of the patients.
Methods: A total of 90 patients diagnosed with bladder cancer, 60 with low-grade tumors and 30 with high-grade tumors were included in this study. To detect mutations in the TERT gene in the DNA samples obtained, the most frequently mutated region of the gene was amplified by PCR using forward and reverse primers and mutation analysis was performed by sequence analysis.
Results: TERT promoter mutation was positive in 38 and negative in 22 out of 60 patients in the low grade group, and positive in 26 and negative in 4 out of 30 patients in the high grade group. Patients with high-grade tumors were 1.940 times more likely to be TERT promoter mutation positive than low-grade patients (p=0.027)
Conclusion: When interpreted together with other studies that have obtained significant results that TERT mutation analysis can be used in diagnosis, tumor grading and follow-up, it is thought that it can be used in the grading and follow-up algorithm.

Keywords : Bladder cancer, telomerase activity, TERT mutation

Download Article


1. Dobruch J, Oszczudlowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021;57(8):749. doi:10.3390/medicina 57080749
2. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241. doi:10.1016/j.eururo.2012.07.033
3. Lotan Y. Clinical presentation, diagnosis, and staging of bladder cancer. 2023, UpToDate.
4. Cancer Stat Facts: Bladder Cancer, E. Surveillance, and End Results Program, Editor., National Cancer Institute: USA.
5. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol. 2011;42(4):455-481. doi:10.1016/j.humpath.2010.07.007
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. doi:10.1016/s0092-8674(00)81683-9
7. Wong JM, Collins K. Telomere maintenance and disease. Lancet. 2003; 362(9388):983-988. doi:10.1016/S0140-6736(03)14369-3
8. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97(4):503-514. doi:10.1016/s0092-8674(00) 80760-6
9. Atlı K, Bozcuk AN. Telomere and cellular ageing. Turk J Geriatr. 2002; 5(3):111-114.
10. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110(43):17426-17431. doi:10.1073/pnas.1310522110
11. Palsgrove DN, Taheri D, Springer SU, et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol. 2019;85:1-9. doi:10.1016/j.humpath.2018.10.033
12. Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013;73(24):7162-7167. doi:10.1158/ 0008-5472.CAN-13-2498
13. Cowan ML, Springer S, Nguyen D, et al. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Hum Pathol. 2016;53:8-13. doi:10.1016/j.humpath.2016.02.009
14. Cowan M, Springer S, Nguyen D, et al. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod Pathol. 2016;29(5):511-515. doi:10.1038/modpathol.2016.53
15. Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014;7:47. doi:10.1186/s13045- 014-0047-7
16. Laukhtina E, Shim SR, Mori K, et al. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4(6):927-942. doi:10.1016/j.euo.2021.10.003
17. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15):6021-6026. doi:10.1073/pnas.1303607110
18. Siraj AK, Bu R, Iqbal K, et al. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Genomics. 2020;112(2):1746-1753. doi:10.1016/j.ygeno. 2019.09.017
19. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res. 1998;4(7):1603-1608.
20. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014; 65(2):360-366. doi:10.1016/j.eururo.2013.08.052
21. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2014;65(2):367-369. doi:10.1016/j.eururo.2013.08. 057
22. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12(10):1637-1638. doi:10.4161/cc.24662
23. Pakmanesh H, Anvari O, Forey N, et al. TERT promoter mutations as simple and non-invasive urinary biomarkers for the detection of urothelial bladder cancer in a high-risk region. Int J Mol Sci. 2022;23(22): 14319. doi:10.3390/ijms232214319
24. Carrasco R, Ingelmo-Torres M, Gómez A, et al. Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. World J Urol. 2022;40(8):2033-2039. doi:10.1007/s00345-022-04061-9
25. Wang K, Liu T, Liu C, et al. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist. 2015;20(3):263-269. doi:10.1634/theoncologist.2014-0391
26. Lin Y, Miyamoto H, Fujinami K, et al. Telomerase activity in human bladder cancer. Clin Cancer Res. 1996;2(6):929-932.
27. Morozov A, Potoldykova N, Chinenov D, et al. hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: a systematic review. Urol Oncol. 2021;39(8):498.e21-498.e33. doi:10.1016/j.urolonc.2021.01.022
Article available in :
Volume 3, Issue 1, 2025
Page : 10-14
https://doi.org/10.51271/ICJIM-0049
Article Information
Received : 03 Kas 2024
Accepted : 08 Ara 2024
Published : 07 Şub 2025
Corresponding Author :

Mustafa Kaplan: Department of Internal Medicine, Sultan 2. Abdulhamid Han Training and Research Hospital, İstanbul, Turkiye

[email protected]
Citation : Kaplan M, Seçgin Demir E, Yılmaz İ, et al. Comparative analysis of human telomerase reverse transcriptase mutation in transitional epithelial cell bladder cancer in high and low grade tumors. Intercont J Int Med. 2025;3(1):10-14.

Read: 59
Cited: 0
Download : 77
_Footer